Study S000489

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04867785
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 281
Start: 2021-05-13
Primary completion: 2022-07-08
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes
Interventions: DRUG:LY3437943; DRUG:Dulaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBD

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, 24 Weeks]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008617	Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Ruotolo G, Diabetes, obesity & metabolism	2026	Randomized trial	PMID 42608321 DOI	cites ClinicalTrials.gov:NCT04867785; registry reference DERIVED:42608321
R0010009	Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Coskun T, The lancet. Diabetes & endocrinology	2025	Randomized trial	PMID 40609566 DOI	cites ClinicalTrials.gov:NCT04867785; registry reference DERIVED:40609566
R0045830	Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels Yi Wen, European Heart Journal	2024	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04867785
R0012625	Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Rosenstock J, Lancet (London, England)	2023	Randomized trial	PMID 37385280 DOI	cites ClinicalTrials.gov:NCT04867785; registry reference DERIVED:37385280